{"type":"trials","record":{"id":86137,"source_id":"isrctn","external_id":"ISRCTN49147196","title":"An observational study to understand markers indicating disease progression in dry age-related macular degeneration","brief_summary":"AMD is a major public health burden, but disease mechanisms remain unknown resulting in several failures in drug development including inconclusive trials for this condition. Choosing new onset GA as an endpoint for the prevention of the progression of intermediate age-related macular degeneration (iAMD) trials will likely require outcome trials with long follow-ups. There is an unmet need to find an imaging biomarker that is a precursor to new onset GA. Similarly, novel imaging biomarkers that predict the growth rate of GA will be valuable in identifying the GA phenotype with fast progression. The major issues of new treatment development are: (a) Complexity of disease mechanism: The primary structure that is affected in GA is not yet identified. It is also unclear whether GA is driven by a single pathogenesis. Questions remain whether GA is caused by primary RPE failure or photoreceptor layer or choriocapillaris are affected first before RPE cell loss. Deciphering the differences in various GA phenotypes may result in fewer drug failures. (b) Lack of potential surrogate markers: To test potential new interventions in AMD, we urgently need new robust early end points that occur b…","overall_status":"Recruiting","phases":[],"study_type":"Observational","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","enrollment":213,"countries":["United Kingdom","England"],"start_date":"2023-10-30","completion_date":"2026-11-30","last_update_date":"2026-09-01","source_url":"https://www.isrctn.com/ISRCTN49147196","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:45:21.717702+00:00","last_seen_at":"2026-09-26T12:27:04.896+00:00","metadata":{"sex":"All","age_range":"Mixed","comparator":null,"attribution":"Source: ISRCTN ISRCTN49147196; retrieved 2026-09-26","interventions":["Other"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["1. For intermediate age-related macular degeneration (iAMD) group, time to conversion from iAMD to nGA/iRORA/cRORA/ hyp…","1. Change from baseline in choroidal thickness at 3, 6 and 12 months. 2. Change from baseline in choroidal choriocapill…"],"design_description":"Observational","source_has_results":false},"controlled_terms":["Age-related macular degeneration - intermediate AMD and geographic atrophy","This is a prospective, observational study in two cohorts of participants with intermediate age-related macular degener…","Participant information sheet","Other"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-26T12:27:05.193853+00:00","duplicate_cluster_key":"id:isrctn49147196","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-10-30 to 2026-11-30","comparator":null,"confidence":"structured-source","population":"All · Mixed","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-26T12:27:04.898Z","intervention":["Other"],"participants":213,"study_design":"Observational","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["1. For intermediate age-related macular degeneration (iAMD) group, time to conversion from iAMD to nGA/iRORA/cRORA/ hyp…","1. Change from baseline in choroidal thickness at 3, 6 and 12 months. 2. Change from baseline in choroidal choriocapill…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Observational."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/86137","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}